Last reviewed · How we verify

Medroxyprogesterone 17-Acetate — Competitive Intelligence Brief

Medroxyprogesterone 17-Acetate (Medroxyprogesterone 17-Acetate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Progestin. Area: Women's Health / Contraception / Hormone Replacement.

marketed Progestin Progesterone receptor Women's Health / Contraception / Hormone Replacement Small molecule Live · refreshed every 30 min

Target snapshot

Medroxyprogesterone 17-Acetate (Medroxyprogesterone 17-Acetate) — Women's Health Care Clinic, Torrance, California. Medroxyprogesterone acetate is a synthetic progestin that suppresses gonadotropin-releasing hormone (GnRH) and inhibits ovulation by acting on the hypothalamic-pituitary-ovarian axis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Medroxyprogesterone 17-Acetate TARGET Medroxyprogesterone 17-Acetate Women's Health Care Clinic, Torrance, California marketed Progestin Progesterone receptor
Natazia DIENOGEST Mochida Pharmaceutical Co., Ltd. marketed Progestin Progesterone receptor 2010-01-01
Faslodex fulvestrant AstraZeneca marketed Estrogen Receptor Antagonist [EPC] Progesterone receptor 2002-01-01
Ortho Evra NORELGESTROMIN marketed Estrogen [EPC] Progesterone receptor 2001-01-01
Elocon MOMETASONE FUROATE Merck & Co. marketed Corticosteroid Progesterone receptor 1987-01-01
Gynorest DYDROGESTERONE Solvay marketed dydrogesterone Progesterone receptor 1982-01-01
Progesterone Progesterone plus HCG Dunamenti REK Istenhegyi IVF Center marketed Progesterone [EPC] progesterone receptor, luteinizing hormone/choriogonadotropin receptor 1978-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Progestin class)

  1. · 2 drugs in this class
  2. Trieu, Nguyen Thi, M.D. · 2 drugs in this class
  3. Bristol-Myers Squibb · 2 drugs in this class
  4. Baylor Research Institute · 1 drug in this class
  5. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  6. Exeltis Usa Inc · 1 drug in this class
  7. IBSA Institut Biochimique SA · 1 drug in this class
  8. Hillel Yaffe Medical Center · 1 drug in this class
  9. Fdn Consumer · 1 drug in this class
  10. Bio Meds Pharmaceutica Ltda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Medroxyprogesterone 17-Acetate — Competitive Intelligence Brief. https://druglandscape.com/ci/medroxyprogesterone-17-acetate. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: